Sign in

Trial result ·

All-Trans Retinoic Acid plus Eltrombopag for Refractory/Relapsed Immune Thrombocytopenia.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This study looked at adults with immune thrombocytopenia, or ITP. All had low platelet counts at the start. Glucocorticoid drugs had not worked, or the illness came back. People were split by chance into equal groups. One group took eltrombopag alone. The other group also took ATRA for 12 weeks. Doctors and patients knew which drugs were given. The trial took place at many centers.

What they found

The main goal was a lasting response at 18 months. That meant enough platelets, with no rescue drugs. It also meant no clinically significant bleeding. There were 48 people in each group. With ATRA added, 29 of 48 had a lasting response. With eltrombopag alone, 17 of 48 did. The added drug was also linked to more full responses. The middle response length was 75 weeks with ATRA, versus 37 weeks without. Side effects were similar in both groups. There were no severe side effects and no deaths from the drugs.

What it means for patients

The authors compared ATRA plus eltrombopag with eltrombopag alone. The ATRA course lasted 12 weeks. With both drugs, more people had a lasting response at 18 months. This was in adults whose ITP resisted glucocorticoids or came back.

Why it is not certain yet

Everyone knew which drugs were given in this trial. This can affect how results are judged. The groups were not fully alike at the start. More people in the ATRA group had clinically significant bleeding at the start. The abstract does not give results past 18 months.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

All-Trans Retinoic Acid plus Eltrombopag for Refractory/Relapsed Immune Thrombocytopenia.

PubMed · PMID 42517709

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Immune thrombocytopenia (ITP) publications